Aprotinin and epsilon aminocaproic acid are effective in reducing blood loss after primary total hip arthroplasty - A prospective randomized double-blind placebo-controlled study

Journal of Thrombosis and Haemostasis

Volumn 3, Issue 7, 2005, Pages 1421-1427

  Ray, M ^a   Hatcher, S ^b   Whitehouse, S L ^c   Crawford, S ^b   Crawford, R ^b,c  

^a QUEENSLAND HEALTH   (Australia)

^b THE PRINCE CHARLES HOSPITAL   (Australia)

^c QUEENSLAND UNIVERSITY OF TECHNOLOGY   (Australia)

Author keywords

Aprotinin; Arthroplasty; Bleeding; Epsilon amino caproic acid; Hip; Transfusion

Indexed keywords

ACETYLSALICYLIC ACID; AMINOCAPROIC ACID; ANTIFIBRINOLYTIC AGENT; APROTININ; CD40 LIGAND; D DIMER; KALLIKREIN INHIBITOR; PADGEM PROTEIN; PLACEBO; FIBRIN DEGRADATION PRODUCT; FIBRIN FRAGMENT D; HEMOSTATIC AGENT;

ADULT; AGED; ARTICLE; BLEEDING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DEMOGRAPHY; DOUBLE BLIND PROCEDURE; DRUG DOSE REGIMEN; DRUG MECHANISM; DRUG SAFETY; FLOW CYTOMETRY; HUMAN; MONOCYTE; POSTOPERATIVE HEMORRHAGE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTE AGGREGATION; TOTAL HIP PROSTHESIS; BIOSYNTHESIS; BLOOD; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HIP ARTHROPLASTY; MALE; METABOLISM; MIDDLE AGED; PROSPECTIVE STUDY; THROMBOCYTE; TIME; TREATMENT OUTCOME;

6-AMINOCAPROIC ACID; AGED; AGED, 80 AND OVER; ANTIFIBRINOLYTIC AGENTS; APROTININ; ARTHROPLASTY, REPLACEMENT, HIP; BLOOD PLATELETS; CD40 LIGAND; DOUBLE-BLIND METHOD; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; FLOW CYTOMETRY; HEMOSTATICS; HUMANS; MALE; MIDDLE AGED; MONOCYTES; P-SELECTIN; PLACEBOS; POSTOPERATIVE HEMORRHAGE; PROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME;

EID: 25144450153     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2005.01457.x     Document Type: Article

References (38)

1. Ray MJ, O'Brien MF. Comparison of epsilon aminocaproic acid and low-dose aprotinin in cardiopulmonary bypass: efficiency, safety and cost. Ann Thorac Surg 2001; 71: 838-43.
2. Lentschener C, Benhamou D, Mercier FJ, Boyer-Neumann C, Naveau S, Smadja C, Wolf M, Franco D. Aprotinin reduces blood loss in patients undergoing elective liver resection. Anesth Analg 1997; 84: 875-81.
3. Jeserschek R, Clar C, Aigner P, Rehak P, Primus B, Windhager R. Reduction of blood loss using high-dose aprotinin in major orthopaedic surgery. J Bone Joint Surg (Br) 2003; 85-B: 174-7.
4. Capdevila X, Calvet Y, Biboulet P, Biron C, Rubenovitch J, d'Athis F. Aprotinin decreases blood loss and homologous transfusions in patients undergoing major orthopaedic surgery. Anesthesiology 1998; 88: 50-7.
5. Lentschener C, Cottin P, Bouaziz H, Mercier FJ, Wolf M, Aljabi Y, Boyer-Neumann C, Benhamou D. Reduction of blood loss and transfusion requirement by aprotinin in posterior lumbar spine fusion. Anesth Analg 1999; 89: 590-7.
6. Murkin JM, Shannon NA, Bourne RB, Rorabeck CH, Cruickshank M, Wyile G. Aprotinin decreases blood loss in patients undergoing revision or bilateral total hip arthroplasty. Anesth Analg 1995; 80: 343-8.
7. Samama CM, Langeron O, Rosencher N, Capdevila X, Rouche P, Pegoix M, Berniere J, Coriat P. Aprotinin versus placebo in major orthopedic surgery: a randomised, double-blinded dose-ranging study. Anesth Analg 2002; 95: 287-93.
8. Janssens M, Joris J, David JL, Lemaire R, Lamy M. High dose aprotinin reduces blood loss in patients undergoing total hip replacement surgery. Anesthesiology 1994; 80: 23-9.
9. Murkin JM, Haig DB, Beer KJ, Cicutti N, McCutchen J, Comunale ME, Hall R, Ruzicka BB. Aprotinin decreases exposure to allogeneic blood during primary unilateral total hip replacement. J Bone Joint Surg [Am] 2000; 82-A: 675-84.
10. D'Ambrosio A, Borghi B, D'Amato G, Antonacci D, Valeri F. Reducing perioperative blood loss in patients undergoing total hip arthroplasty. Int J Artif Organs 1999; 22: 47-51.
11. Langdown AJ, Field J, Grote J, Himayat H. Aprotinin (Trasylol) does not reduce bleeding in primary total hip arthroplasty. J Arthroplasty 2000; 15: 1009-12.
12. Hayes A, Murphy DB, McCarrol M. The efficacy of single-dose aprotinin 2 million KIU in reducing blood loss and its impact on the incidence of deep venous thrombosis in patients undergoing total hip replacement surgery. J Clin Anesth 1996; 8: 357-60.
13. Lentschener C, Benhamou D. The blood sparing effect of aprotinin should be revisisted (letter). Anesthesiology 1998; 89: 1598-9.
14. Kasper SM, Elsner F, Hilger D, Grond S, Rutt J. A retrospective study of the effects of small-dose aprotinin on blood loss and transfusion needs during total hip arthroplasty. Eur J Anaesthesiology 1998; 15: 669-75.
15. Florentino-Pineda I, Blakemore LC, Thompson GH, Poe-Kochert C, Adler P, Tripi P. The effect of E-aminocaproic acid on perioperative blood loss in patients with idiopathic scoliosis undergoing posterior spinal fusion. Spine 2001; 26: 1147-51.
16. Urban MK, Beckman J, Gordon M, Urquhart B, Boachie-Adjei O. The efficacy of antifibrinolytics in the reduction of blood loss during complex adult reconstructive spine surgery. Spine 2001; 26: 1152-7.
17. Hartley BJ, Beaupre LA, Jones CA, Cinats JG, Guenther CR. The effect of epsilon aminocaproic acid on blood loss in patients who undergo primary total hip replacement: a pilot study. Can J Surg 2002; 45: 185-90.
18. van Oeveren W, Jansen NJ, Bidstrup BP, Royston D, Westaby S, Neuhof H, Wildevuur CR. Effects of aprotinin on hemostratic mechanisms during cardiopulmonary bypass. Ann Thorac Surg 1987; 44: 640-5.
19. Ray MJ, Marsh NA. Aprotinin reduces blood loss after cardiopulmonary bypass by direct inhibition of plasmin. Thromb Haemost 1997; 78: 1021-6.
20. Ueshima S, Okada K, Matsuo O. Stabilization of plasmin by lysine derivatives. Clin Chim Acta 1996; 245: 7-18.
21. Ray MJ, Hales M, Marsh N. Epsilon-aminocaproic acid promotes the release of alpha2-antiplasmin during and after cardiopulmonary bypass. Blood Coagul Fibrinol 2001; 12: 129-35.
22. Ray MJ, Marsh NA, Mengersen K. A brief review of studies evaluating the adverse effects of aprotinin therapy in aortocoronary bypass surgery. Thromb Haemostas 1997; 77: 1038-40.
23. Ray MJ, Marsh NA, Just SJ, Perrin EJ, O'Brien MF, Hawson GA. Preoperative platelet dysfunction increases the benefit of aprotinin in cardiopulmonary bypass. Ann Thorac Surg 1997; 63: 57-63.
24. Royston D. Aprotinin versus lysine analogues: the debate continues. Ann Thorac Surg 1998; 65(4 Suppl): S9-19; discussion S27-8.
25. Yang LC, Wang CJ, Lee TH, Lin FC, Yang BY, Lin CR, Lee TC. Early diagnosis of deep vein thrombosis in female patients who undergo total knee arthroplasty with measurement of P-selectin activation. J Vasc Surg 2002; 35: 707-12.
26. Freedman JE, Loscalzo J. Platelet-monocyte aggregates: bridging thrombosis and inflammation. Circulation 2002; 105: 2130-2.
27. Furman MI, Krueger LA, Frelinger III AL, Barnard MR, Mascelli MA, Nakada MT, Michelson AD. GPIIb-IIIa antagonist-induced reduction in platelet surface factor V/Va binding and phosphatidylserine expression in whole blood. Thromb Haemost 2000; 84: 492-8.
28. André P, Nannizzi-Alaimo L, Prasad SK, Phillips DR. Platelet-derived CD40L: the switch-hitting player of cardiovascular disease. Circulation 2002; 106: 896-9.
29. Benoni G, Lethagen S, Fredin H. The effect of transexamic acid on local and plasma fibrinolysis during total knee arthroplasty. Thromb Res 1997; 85: 195-206.
30. Westrich GH, Allen ML, Tarantino SJ, Ghelman B, Schneider R, Laskin RS, Haas SB, Sculco TP. Ultrasound screening for deep venous thrombosis after total knee arthroplasty. 2-year reassessment. Clin Orthop 1998; 356: 125-33.
31. Greilich PE, Brouse CH, Rinder CS, Smith BR, Sandoval BA, Rinder HM, Eberhart RC, Jessen ME. Effects of [epsilon]-aminocaproic acid and aprotinin on leucocyte-platelet adhesion in patients undergoing cardiac surgery. Anesthesiology 2004; 100: 225-33.
32. Santamaria A, Mateo J, Muniz-Diaz E, Oliver A, Murillo J, Litvan H, Souto JC, Fontcuberta J. Platelet function during cardiopulmonary bypass not changed by two different doses of aprotinin. Haematologica 2000; 85: 381-5.
33. Kestin AS, Valeri CR, Khuri SF, Loscalzo J, Ellis PA, MacGregor H, Birjiniuk V, Ouimet H, Pasche B, Nelson MJ, Benoit SE, Rodino LJ, Barnard MR, Michelson AD. The platelet function defect of cardiopulmonary bypass. Blood 1993; 82: 107-17.
34. Laupacis A, Fergusson D. Drugs to minimise perioperative blood loss in cardiac surgery: meta-analyses using perioperative blood transfusion as the outcome. The International Study of Peri-Operative Transfusion (ISPOT) Investigators. Anesth Analg 1997; 85: 1258-67.
35. Llau JV, Garcia-Perez ML. Safe administration of aprotinin in orthopedic surgery (letter). Orthopedics 2001; 24: 529.
36. Dietrich W. Incidence of hypersensitivity reactions. Ann Thorac Surg 1998; 65(6 Suppl): S60-4; discussion S74-6.
37. Dietrich W, Spath P, Ebell A, Richter JA. Prevalence of anaphylactic reactions to aprotinin: analysis of two hundred forty-eight reexposures to aprotinin in heart operations. J Thorac Cardiovasc Surg 1997; 113: 194-201.
38. Pecquet C, Autegarden JE, Kural-Menasche S, Perez G, Menasche P, Sanson-LePors MJ, Abuaf N, Leynadier F. Anaphylactic reactions to aprotinin: intradermal diagnostic tests. Ann Fr Anesth Reanim 2000; 19: 755-7.